These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 15369394

  • 1. Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period.
    Peleg-Shulman T, Tsubery H, Mironchik M, Fridkin M, Schreiber G, Shechter Y.
    J Med Chem; 2004 Sep 23; 47(20):4897-904. PubMed ID: 15369394
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ, Fam CM, Chlipala EA, Carlson SJ, Lee JI, Rosendahl MS, Doherty DH, Cox GN.
    Bioconjug Chem; 2008 Jan 23; 19(1):299-305. PubMed ID: 18020402
    [Abstract] [Full Text] [Related]

  • 4. Reversible pegylation of insulin facilitates its prolonged action in vivo.
    Shechter Y, Mironchik M, Rubinraut S, Tsubery H, Sasson K, Marcus Y, Fridkin M.
    Eur J Pharm Biopharm; 2008 Sep 23; 70(1):19-28. PubMed ID: 18495444
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Turning low-molecular-weight drugs into prolonged acting prodrugs by reversible pegylation: a study with gentamicin.
    Marcus Y, Sasson K, Fridkin M, Shechter Y.
    J Med Chem; 2008 Jul 24; 51(14):4300-5. PubMed ID: 18578475
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Conjugation of PolyPEG to interferon alpha extends serum half-life while maintaining low viscosity of the conjugate.
    Podobnik B, Helk B, Smilović V, Škrajnar Š, Fidler K, Jevševar S, Godwin A, Williams P.
    Bioconjug Chem; 2015 Mar 18; 26(3):452-9. PubMed ID: 25629733
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Thiolytically cleavable dithiobenzyl urethane-linked polymer-protein conjugates as macromolecular prodrugs: reversible PEGylation of proteins.
    Zalipsky S, Mullah N, Engbers C, Hutchins MU, Kiwan R.
    Bioconjug Chem; 2007 Mar 18; 18(6):1869-78. PubMed ID: 17935288
    [Abstract] [Full Text] [Related]

  • 14. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
    Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu D, Zhang Z, Hua J, Hsieh MC, Zhou J, Petti G, Li X, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D.
    Bioconjug Chem; 2006 Mar 18; 17(3):618-30. PubMed ID: 16704199
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Development of poly(ethylene glycol) conjugated lactoferrin for oral administration.
    Nojima Y, Suzuki Y, Iguchi K, Shiga T, Iwata A, Fujimoto T, Yoshida K, Shimizu H, Takeuchi T, Sato A.
    Bioconjug Chem; 2008 Nov 19; 19(11):2253-9. PubMed ID: 18834167
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.